Psychedelics vs. Cannabis: Is Reform Following the Same Playbook?

August 26, 2026

Photo by adege via Pixabay.

Two federal actions landed eight days apart in April 2026, and anyone who lived through the cannabis reform wars couldn't help but notice the parallels. On April 18, President Trump signed Executive Order 14401, ordering federal agencies to fast-track rescheduling reviews for Schedule I substances that have completed Phase 3 clinical trials, with explicit direction to accelerate psychedelic therapy access for veterans and patients with treatment-resistant mental illness. Five days later, the DOJ issued Attorney General Order No. 6754-2026, moving FDA-approved marijuana and state-licensed medical marijuana from Schedule I to Schedule III. Same week, same administration, same underlying theory of change.

That theory isn't legalization and it isn't decriminalization -- it's medical access through tightly controlled channels, with the federal government picking winners based on clinical evidence rather than ballot-box sentiment. Cannabis took a winding, multi-decade path to get anywhere close to this point, running through decriminalization statutes, medical marijuana ballot measures, and eventually adult-use legalization in over twenty states. Psychedelics appear to be skipping straight to the medicalized middle. The question worth sitting with: is this the start of psychedelics repeating cannabis's slow, state-by-state legalization arc, or are we watching an entirely different playbook get written in real time, one built around clinical trials and legislative pilot programs instead of grassroots ballot campaigns?

April 2026: Two Schedule I Fights, One Week Apart

Photo by mari_di_ann via Pixabay.

The timing of these two orders wasn't coincidental so much as it was structurally linked. Executive Order 14401 targets any Schedule I substance that has cleared Phase 3 trials, which right now effectively means MDMA and, to a lesser extent, psilocybin formulations moving through the FDA pipeline. The order doesn't reschedule anything itself -- it directs the DEA, HHS, and FDA to move faster on reviews already in motion, and it specifically calls out expanded access for serious mental illness and treatment-resistant PTSD.

DOJ's AG Order No. 6754-2026, by contrast, deals with something already further along: it shifts FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III. That's a real, if narrow, reclassification. What it doesn't do is settle the bigger question. A separate administrative hearing starting June 29, 2026 will determine whether marijuana as a whole -- not just approved pharmaceutical formulations -- gets moved to Schedule III. Until that hearing resolves, most state-legal recreational cannabis remains in a legal gray zone federally, exactly where it's sat for years.

Psilocybin, MDMA, and ibogaine, meanwhile, still have zero FDA-approved products and remain fully Schedule I. What's changed is the review clock, not the classification. Both tracks point toward the same structural preference: expand access through medical channels and clinical evidence, not through broad decriminalization or adult-use frameworks. The echo is real, but the timelines and mechanisms aren't identical -- cannabis is negotiating the terms of an existing gray-market reality, while psychedelics are still trying to get a single product across the FDA finish line.

Public Opinion: Psilocybin Is Where Cannabis Was in the 1980s

Photo by athree23 via Pixabay.

Public opinion on psychedelics is running well behind where cannabis was when California voters passed Prop 215 in 1996. A 2025 RAND survey found that just 23% of American adults support legal psilocybin use, with support for MDMA and LSD sitting closer to 10%. Analysts studying the psychedelic reform movement have started pointing to Gallup's marijuana tracking data as the closest available comparison -- and 23% support lines up almost exactly with where cannabis legalization sentiment sat through much of the late 1970s into the mid-1990s, a period when public opinion moved in fits and starts rather than a steady climb.

That's an important marker because Prop 215 didn't pass in a vacuum. By 1996, cannabis support had already climbed substantially past that 23% baseline, buoyed by AIDS-era advocacy, a wave of state decriminalization laws passed decades earlier, and years of media coverage humanizing medical marijuana patients. Psilocybin doesn't have that runway yet. If psychedelic reform tracks cannabis's opinion curve on a similar timeline, broad public support for legalization could still be a decade or more out, even as individual state legislatures move well ahead of where voters currently sit.

That gap explains a lot about the strategy choices happening right now. Lawmakers and advocacy groups aren't waiting for public opinion to catch up before acting -- they're routing reform through statehouses and clinical frameworks instead, because a ballot initiative asking voters to legalize psilocybin outright would likely underperform in most states today. Medical framing, backed by FDA trial data and veteran advocacy, polls dramatically better than broad legalization language, and reform advocates know it.

States Are Moving, But Through the Legislature, Not the Ballot Box

Photo by 12019 via Pixabay.

More than a dozen states are expected to take up psychedelic legislation or ballot measures during 2026, but the mechanism matters as much as the count. Only Oregon and Colorado currently run fully operational, voter-approved regulated psilocybin programs, both born from ballot initiatives -- Oregon's Measure 109 in 2020 and Colorado's Proposition 122 in 2022. Everything moving since has gone through statehouses instead.

New Mexico's governor signed SB 219, the Medical Psilocybin Act, in April 2025, making it the third state with a comprehensive psilocybin law -- but unlike Oregon and Colorado, it came entirely from the legislature, with no ballot measure involved. New Jersey followed a similar path: Governor Murphy signed S. 2283 on January 20, establishing a Department of Health pilot program overseen by a newly created Psychedelic Therapy and Research Advisory Board, a structure that looks far more like a clinical research initiative than a legalization measure. Virginia took an even more cautious approach, enacting a trigger law that directs its Board of Pharmacy to automatically reschedule an FDA-approved psilocybin formulation if and when federal scheduling changes -- essentially pre-loading state law to follow federal action rather than get ahead of it.

Alaska is the exception that proves the rule. Activists there tried to replicate Colorado's multi-substance ballot model but missed the 2025 signature deadline and are now targeting 2028 instead. That miss says something about the current landscape: the ballot-initiative energy that drove cannabis's later legalization wave hasn't materialized yet for psychedelics, and legislatures are filling the vacuum instead. As always, check your specific state's current statute before assuming any of this applies where you live -- these programs vary enormously in scope, eligibility, and enforcement.

The Big Difference: No Decriminalize-First Strategy

Photo by Ivan Babydov via Pexels.

Here's where the playbooks genuinely diverge. Cannabis reform ran decriminalization first in dozens of states, often for years or decades, before full legalization followed. Personal possession penalties got reduced or eliminated well before anyone was licensing dispensaries, and that decriminalized period built public familiarity and political cover for what came later.

Most 2026 psychedelic bills skip that step entirely. New York's pending approach is a useful example: it's built to develop institutional and clinical expertise, training therapists, funding research, setting up supervised access frameworks, but it explicitly does not decriminalize personal possession or use. That's not an oversight -- it's the design. Lawmakers are betting that medical framing, with its FDA trial data and veteran-advocacy backing, is the fastest route to any legal access at all, and they're not willing to spend political capital on decriminalization language that polls worse.

The practical consequence is stark: someone growing psilocybin mushrooms at home, or possessing them outside a licensed clinical program, remains criminally exposed in most states even where medical psilocybin programs now exist on paper. A patient can potentially access psilocybin therapy through a licensed clinic in New Jersey or New Mexico while a neighbor doing the same substance recreationally faces the same criminal penalties as before either law passed. That's a very different rollout from Oregon and Colorado, where regulated personal use sits alongside supervised therapeutic access.

Regulators clearly drew a lesson from cannabis's messier history, where inconsistent decriminalization created enforcement confusion and uneven access across neighboring jurisdictions. The tradeoff is that personal-use decriminalization for psychedelics may lag far behind the Oregon/Colorado model for years to come. Legality here varies enormously by state and by substance -- MDMA, psilocybin, and ibogaine aren't treated uniformly even within states that have acted -- so don't assume protections in one context extend to another without checking current law directly.

What's happening in 2026 looks less like psychedelics replaying cannabis's history and more like lawmakers borrowing cannabis's regulatory infrastructure -- licensing boards, advisory committees, clinical supervision requirements -- while deliberately skipping the decriminalization phase that gave cannabis reform its grassroots momentum. It's a calculated bet that medical framing can outrun public opinion, moving through statehouses and FDA trial data rather than waiting for the kind of ballot-box majorities that took cannabis two decades to build.

The June 29, 2026 marijuana rescheduling hearing is worth watching closely regardless of which side of this debate you're on. Its outcome will likely set the tone for how aggressively the DEA and FDA handle the psilocybin and MDMA fast-track reviews that Executive Order 14401 set in motion. A cautious, narrow ruling on marijuana suggests agencies will move slowly on psychedelics too; a more expansive one could signal the federal government is genuinely ready to accelerate medical access across multiple Schedule I substances at once.

Given where public support sits today -- roughly where cannabis was nearly three decades before Prop 215 -- don't expect voters to drive this next phase. State legislatures, clinical trial data, and administrative rulemaking are going to shape psychedelic policy for at least the next several years, with ballot initiatives playing a distinctly secondary role until public opinion catches up to where lawmakers already are.